All In Biotech

Drug Trial Radar · NCT05485974

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

A Phase 1, Open Label, Dose Escalation of HBI-2438 in Patients With Advanced Malignant Solid Tumors Harboring KRAS G12C Mutation

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

Aug 1, 2022

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
HUYABIO International, LLC.Industry
Sponsor type
Industry
First posted
Aug 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.

Conditions

  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Colorectal Cancer
  • Cancer of Pancreas
  • Colon Cancer
  • Solid Tumor
  • Cancer

Interventions

  • HBI-2438Drug

    KRAS G12C Inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the maximum tolerated dose (MTD)Time frame: Up to 36 months
  2. adverse events (AEs), and serious adverse events (SAEs) overallTime frame: Up to 36 months

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • California Cancer Associates for Research and Excellence, Inc. (cCare)

    Encinitas, California

  • The Oncology Institute of Hope and Innovation

    Glendale, California

  • The Oncology Institute of Hope and Innovation

    Long Beach, California

  • The Oncology Institute of Hope and Innovation

    Pasadena, California

  • California Cancer Associates for Research and Excellence, Inc. (cCare)

    San Marcos, California

  • The Oncology Institute of Hope and Innovation

    Santa Ana, California

  • Sarcoma Oncology

    Santa Monica, California

  • Innovative Clinical Research Institute (ICRI)

    Whittier, California

  • The Oncology Institute of Hope and Innovation

    Whittier, California

  • BRCR Medical Center

    Plantation, Florida

  • Michigan Center of Medical Research

    Farmington Hills, Michigan

  • Alliance for Multispecialty Research, LLC

    Kansas City, Missouri

  • Gabrail Cancer Center

    Canton, Ohio

  • Pan American Center for Oncology Trials (PanOncology Trials)

    Rio Piedras, Puerto Rico, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.